New cell injection aims to free type 1 diabetes patients from insulin
NCT ID NCT06731218
Summary
This is an early safety study testing a new islet cell injection called RGB-5088 for adults with Type 1 diabetes. The main goal is to see if the treatment is safe and if it can help patients achieve better blood sugar control without severe low blood sugar events. Researchers will also check if any participants can stop using insulin after the injection.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin First Center Hospital
RECRUITINGTianjin, Tianjin Municipality, 300000, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.